Nivolumab post-Ipi en
melanoma:
CheckMate 037
Pembrolizumab post-Ipi en
melanoma:
Keynote 002
Weber et al. Lancet Oncology 2015; SMR 2016
Lancet Oncol 2015, June 24, 2015; ESMO 2016
100% Ipilimumab
22% BRAF mut
100% Ipilimumab
23% iBRAF
98 (55%)
540p
405p
31 (23%)
did not receive tx
